101
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Measuring Impact in Drug Repurposing

      Published
      conference-abstract
        1
      REPO4EU
      RExPO23
      25-26 October 2023
      Impact Factor, Open Science, Open Access, Metrics, Drug repurposing
      Bookmark

            Abstract

            Despite an urgent need for real-world solutions such as new therapies for a host of neglected diseases, the “impact” of academic research in the biomedical sciences is to a large extent measured by a bibliometric benchmark, the “Impact Factor”. This factor only measures the average number of citations to a particular journal within a proprietary data set and reflects nothing about the citations to a single article or impact of specific research results. Nevertheless, the “Impact Factor” remains the central currency of academic research to this day, dictating careers, grants and even the direction of research programs.

            The drug repurposing community has set out to challenge the status quo in drug discovery by questioning current organ-based disease definitions and standard practices for bringing new drugs to market. By applying bioinformatics, in silico and network medicine approaches, machine learning and AI, researchers attempt to shift the paradigm of biomedical research towards more personalized and precision medicine. These digital tools will be most effective in an environment of FAIR data, rapid sharing, structured and networked information. Therefore, new incentives and metrics for academic research are required that encourage open science practices, rather than publication in traditionally “high-impact”, subscription-based journals. A true impact factor might measure the accessibility and reach beyond academic libraries, interoperability with other data sets, citations in the patent literature, reproducibility and scientific rigor. Academia could be a stronger motor for drug repurposing to quickly bring potential therapies to clinical trial and beyond, if incentives were better aligned with metrics of impact that actually measured impact on the lives of patients.

            Content

            Author and article information

            Conference
            REPO4EU
            4 October 2023
            Affiliations
            [1 ] ScienceOpen GmbH, Berlin (Germany);
            Author information
            https://orcid.org/0000-0002-2298-2418
            Article
            10.58647/REXPO.23020
            e14ae7b9-a83e-4829-a3d1-e51d03311628
            Authors

            Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

            RExPO23
            2
            Stockholm, Sweden
            25-26 October 2023
            History
            Product

            REPO4EU

            Categories

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Pharmacology & Pharmaceutical medicine
            Impact Factor,Open Science,Open Access,Metrics,Drug repurposing

            References

            1. Brembs Björn. Prestigious Science Journals Struggle to Reach Even Average Reliability. Frontiers in Human Neuroscience. Vol. 12:2018. Frontiers Media SA. [Cross Ref]

            2. McKiernan Erin C, Schimanski Lesley A, Muñoz Nieves Carol, Matthias Lisa, Niles Meredith T, Alperin Juan P. Use of the Journal Impact Factor in academic review, promotion, and tenure evaluations. eLife. Vol. 8:2019. eLife Sciences Publications, Ltd. [Cross Ref]

            Comments

            Comment on this article